ReviewFrontiers in immunology2017
Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 180 citations in OpenAlex.
- Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.World journal of gastroenterology · 2019Trial
- Climate Change and Food Allergy: Adaptations and Risks at the Intersection of Environment and Health.Comprehensive reviews in food science and food safety · 2026Review
- Obesogenic Diets Composition Differentially Alters theNutrients · 2026Article
- Whey Proteins and Immunity: Mechanisms Underlying Immune System Reinforcement and Protection Against Viral and Bacterial Infections.Nutrients · 2026Review
- From Mycobiome Remodeling to Therapeutic Candidate: Aspergillus ruber and 3-methyldioxyindole, Acknowledged as a Novel Modulator Via BPIS Treatment and Alleviating MASLD.Probiotics and antimicrobial proteins · 2026Article
- Exopolysaccharides fromFoods (Basel, Switzerland) · 2026Article
- Psychosocial aspects and mental health burden of pediatric MASLD.Frontiers in endocrinology · 2026Review
- The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.Frontiers in immunology · 2026Review
- A new type of biomarker for heat stress: insights from immunology.Frontiers in immunology · 2026Review
- Early-onset colorectal cancer as an emerging disease of metabolic dysregulation.Nature reviews. Endocrinology · 2025Review
- Carbohydrate consumption and cirrhosis-related mortality: a prospective cohort study.BMC research notes · 2025Article
- Article
- Fructose-induced progression of steatohepatitis involves disrupting aldolase B-AMPK signaling in methionine adenosyltransferase 1A deficient mice.Metabolism: clinical and experimental · 2025Article
- Does maternal consumption of nutritive and non-nutritive sweeteners result in offspring hypertension?Frontiers in nutrition · 2025Review
- Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review.Cell stress · 2025Review
- Mindful Eating: A Deep Insight Into Fructose Metabolism and Its Effects on Appetite Regulation and Brain Function.Journal of nutrition and metabolism · 2025Review
- Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Nutrients · 2024Review
- Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans.Physiological research · 2024Article
- The Role of Gut Microbiome in Sleep Quality and Health: Dietary Strategies for Microbiota Support.Nutrients · 2024Review
- Fructose malabsorption and fructan malabsorption are associated in patients with irritable bowel syndrome.BMC gastroenterology · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fructose is one of the key dietary catalysts in the development of non-alcoholic fatty liver disease (NAFLD). NAFLD comprises a complex disease spectrum, including steatosis (fatty liver), non-alcoholic steatohepatitis, hepatocyte injury, inflammation, and fibrosis. It is also the hepatic manifestation of the metabolic syndrome, which covers abdominal obesity, insulin resistance, dyslipidemia, glucose intolerance, or type 2 diabetes mellitus. Commensal bacteria modulate the host immune system, protect against exogenous pathogens, and are gatekeepers in intestinal barrier function and maturation. Dysbalanced intestinal microbiota composition influences a variety of NAFLD-associated clinical conditions. Conversely, nutritional supplementation with probiotics and preobiotics impacting composition of gut microbiota can improve the outcome of NAFLD. In crosstalk with the host immune system, the gut microbiota is able to modulate inflammation, insulin resistance, and intestinal permeability. Moreover, the composition of microbiota of an individual is a kind of fingerprint highly influenced by diet. In addition, not only the microbiota itself but also its metabolites influence the metabolism and host immune system. The gut microbiota can produce vitamins and a variety of nutrients including short-chain fatty acids. Holding a healthy balance of the microbiota is therefore highly important. In the present review, we discuss the impact of long-term intake of fructose on the composition of the intestinal microbiota and its biological consequences in regard to liver homeostasis and disease. In particular, we will refer about fructose-induced alterations of the tight junction proteins affecting the gut permeability, leading to the translocation of bacteria and bacterial endotoxins into the blood circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.